Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts
Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research
PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.
Here's Why You Should Add PacBio Stock to Your Portfolio
PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.
Three Genomics Stocks Worth Tracking This Year
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y
PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago.
Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.97, signifying a -5.74% move from its prior day's close.
